These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 15386209)

  • 61. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination.
    Laube BL
    Respir Care; 2005 Sep; 50(9):1161-76. PubMed ID: 16122400
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Aerosol devices and asthma therapy.
    Berger W
    Curr Drug Deliv; 2009 Jan; 6(1):38-49. PubMed ID: 19418954
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
    Munzel U; Marschall K; Fyrnys B; Wedel M
    Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Detection and assessment of co-association in inhalable drug particles using aerosol time-of-flight mass spectrometry.
    New A; Prime D; Zomer S; Elder D; Donovan R; Freney E
    Rapid Commun Mass Spectrom; 2008 Dec; 22(23):3873-82. PubMed ID: 19003851
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.
    Sorino C; Negri S; Spanevello A; Visca D; Scichilone N
    Eur J Intern Med; 2020 May; 75():15-18. PubMed ID: 32113944
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dry powder inhalers for optimal drug delivery.
    Newman SP
    Expert Opin Biol Ther; 2004 Jan; 4(1):23-33. PubMed ID: 14680466
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adherence logger for a dry powder inhaler: a new device for medical adherence research.
    Bogen D; Apter AJ
    J Allergy Clin Immunol; 2004 Oct; 114(4):863-8. PubMed ID: 15480328
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhalation therapy in children with asthma.
    Brand PL
    Minerva Pediatr; 2000 Mar; 52(3):137-42. PubMed ID: 10879004
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
    Hein S; Bur M; Schaefer UF; Lehr CM
    Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dynamic change of the upper airway during inhalation via aerosol delivery devices.
    Ehtezazi T; Horsfield MA; Barry PW; O'Callaghan C
    J Aerosol Med; 2004; 17(4):325-34. PubMed ID: 15684732
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Applicability of DPI formulations for novel neurokinin receptor antagonist.
    Kumon M; Yabe Y; Kasuya Y; Suzuki M; Kusai A; Yonemochi E; Terada K
    Int J Pharm; 2008 May; 356(1-2):102-9. PubMed ID: 18294787
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.
    Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of some parameters influencing the drug delivery from a dry powder inhalation device using an in vitro model of the horse airways.
    Duvivier DH; Chiap P; Crommen J; Lekeux P
    Vet Res; 1997; 28(6):557-64. PubMed ID: 9428149
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Challenges and opportunities in respiratory drug delivery devices.
    Nikander K
    Expert Opin Drug Deliv; 2010 Nov; 7(11):1235-8. PubMed ID: 20939686
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.
    Kawabata Y; Aoki Y; Matsui T; Yamamoto K; Sato H; Onoue S; Yamada S
    Eur J Pharm Biopharm; 2011 Jan; 77(1):178-81. PubMed ID: 21081161
    [TBL] [Abstract][Full Text] [Related]  

  • 77. On the use of dry powder inhalers in situations perceived as constrained.
    Borgström L
    J Aerosol Med; 2001; 14(3):281-7. PubMed ID: 11693839
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Inhalation techniques in the treatment of asthma].
    Rodríguez M; Celay E; Larrea I; Urdánoz M; Zabalegui A; Ollo B
    An Sist Sanit Navar; 2003; 26 Suppl 2():139-46. PubMed ID: 13679973
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Formulation development of inhalation powders for FK888 with carrier lactose using Spinhaler and its absorption in healthy volunteers.
    Nakate T; Yoshida H; Ohike A; Tokunaga Y; Ibuki R; Kawashima Y
    J Control Release; 2004 May; 97(1):19-29. PubMed ID: 15147801
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma.
    Capstick TG; Clifton IJ
    Expert Rev Respir Med; 2012 Feb; 6(1):91-101; quiz 102-3. PubMed ID: 22283582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.